1 |
Subramaniyan S, Terrando N. Neuroinflammation and perioperative neurocognitive disorders [J]. Anesth Analg, 2019, 128(4): 781-788.
|
2 |
Kawai Y. Delusional misidentification syndromes in organic brain disorders [J]. Brain Nerve, 2018 ,70(11): 1181-1191.
|
3 |
Kishi T, Yoshimura R, Sakuma K, et al. Lurasidone, Olanzapine, and Quetiapine extended-release for bipolar depression: A systematic review and network meta-analysis of phase 3 trials in Japan [J]. Neuropsychopharmacol Rep, 2020, 40(4): 417-422.
|
4 |
姜飞. 喹硫平与奥氮平治疗老年器质性精神障碍的疗效分析 [J]. 中国现代药物应用, 2021, 15(3): 210-212.
|
5 |
晏丽丽. 喹硫平与奥氮平治疗脑器质性精神障碍疗效比较 [J]. 临床医药文献电子杂志, 2020, 7(16): 152.
|
6 |
中华医学会精神分会. 中国精神障碍分类与诊断标准第3版 [M]. 济南: 山东科学技术出版社, 2001: 9-168.
|
7 |
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia [J]. Schizophr Bull, 1987, 13(2): 261-276.
|
8 |
沈渔屯. 精神病学 [M]. 5版. 北京: 人民卫生出版社, 2009: 935.
|
9 |
Peter F, Andrea S, Nancy A. Forty years of structural brain imaging in mental disorders: is it clinically useful or not? [J]. Dialogues Clin Neurosci, 2018, 20(3): 179-186.
|
10 |
Drossman DA, Tack J, Ford AC, et al. Neuromodulators for functional gastrointestinal disorders (disorders of gut-brain interaction): a rome foundation working team report [J]. Gastroenterology, 2018, 154(4): 1140-1171.e1.
|
11 |
Robinson BD, Isbell CL, Anasooya Shaji C,et al. Quetiapine protects the blood-brain barrier in traumatic brain injury [J]. J Trauma Acute Care Surg, 2018, 85(5): 968-976.
|
12 |
Gjerde PB, Jørgensen KN, Steen NE, et al. Association between Olanzapine treatment and brain cortical thickness and gray/white matter contrast is moderated by cholesterol in psychotic disorders [J]. Psychiatry Res Neuroimaging, 2018, 282(12): 55-63.
|
13 |
Alonso-Pedrero L, Bes-Rastrollo M, Marti A. Effects of antidepressant and antipsychotic use on weight gain: a systematic review [J]. Obes Rev, 2019, 20(12): 1680-1690.
|
14 |
Jain S, Bhargava M, Gautam S. Weight gain with Olanzapine: drug, gender or age? [J]. Indian J Psychiatry, 2006, 48(1): 39-42.
|
15 |
Martin WF, Correll CU, Weiden PJ, et al. Mitigation of Olanzapine-induced weight gain with Samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia [J]. Am J Psychiatry, 2019, 176(6): 457-467.
|
16 |
Correll CU, Newcomer JW, Silverman B, et al. Effects of Olanzapine combined with Samidorphan on weight gain in schizophrenia: a 24-week phase 3 study [J]. Am J Psychiatry, 2020, 177(12): 1168-1178.
|
17 |
Minet-Ringuet J, Even PC, Valet P, et al. Alterations of lipid metabolism and gene expression in rat adipocytes during chronic Olanzapine treatment [J]. Mol Psychiatry, 2007, 12(6): 562-571.
|
18 |
胡红霞, 赵倩, 白天山, 等. 利培酮和氯氮平、喹硫平对精神分裂症患者脂代谢影响比较 [J]. 中国卫生检验杂志, 2012, 22(12): 2878-2879.
|
19 |
Kishi T, Ikuta T, Matsuda Y, et al. Quetiapine extended-release vs olanzapine for Japanese patients with bipolar depression: a bayesian analysis [J]. Neuropsychopharmacol Rep, 2019, 39(3): 256-259.
|
20 |
吴小立, 魏钦令, 钟智勇, 等. 阿立哌唑与奥氮平对首发年轻成人精神分裂症患者短期内代谢风险的比较 [J]. 中山大学学报(医学科学版), 2011, 32(5): 653-658.
|